Logo Image
|Articles|April 15, 2002

BioPharm International

  • BioPharm International-04-01-2002
  • Volume 15
  • Issue 4

Advances in Amino Acid Analysis

by John C. Anders, AAI International With the advent of proteomics, innovative protein-based pharmaceuticals are entering the drug development pipeline. Compositional analysis, protein quantitation, and absorptivity determination by amino acid analysis ensures accurate characterization of recombinant proteins, amino acids, and peptides in development, bulk, and final products.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 24 years ago

Analytical Advances: Paperless or Less Paper?

over 24 years ago

Outsourcing Outlook: Public CROs Craft New Strategies to Achieve Financial and Strategic Objectives

over 24 years ago

Storing an Ion-Exchange Chromatography Gel in Dilute Alkali During Recycling Improves Cleaning

over 24 years ago

Beyond QSIT

over 24 years ago

Determining Protein Concentration, Part 1: Methodology

over 24 years ago

Guest Editorial: The Protein Production Challenge

over 24 years ago

Business Matters: Personalized Medicine or Blockbusterology?

over 24 years ago

Analytical Advances: High-Throughput Purification System for Oligonucleotides Improves Synthetic Gene Production

Related to this article

View more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more